Medtronic has announced data demonstrating that the company’s Heli-FX EndoAnchor system enhances outcomes and durability in patients with complex aortic abdominal aneurysm (AAA) anatomy, particularly those who have hostile aortic neck anatomy.
Teleflex’ Arrow Vascular positioning system (VPS) Rhythm device with optional TipTracker technology has been issued 510(k) clearance from the US Food and Drug Administration (FDA) to commercialise the device in the USA.
The MAJESTIC trial set out to evaluate the performance of the Eluvia paclitaxel-eluting vascular stent system (Boston Scientific) in the treatment of femoropopliteal artery lesions. Two-year results show a greater than 90% freedom from target lesion revascularisation rate.
A preliminary analysis suggests that thermal ablation may be effective in selected patients with local small cell lung cancer without adjuvant therapy. The research from Brown University, Providence, USA was published in the Journal of Vascular and Interventional Radiology (JVIR).
Liver cancer researchers from France and Singapore collaborate on a prospective meta-analysis of two studies of Y-90 resin microspheres vs. sorafenib in patients with unresectable hepatocellular carcinoma.
A new study presented at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE 2016, 10–14 September, Barcelona, Spain) meeting finds that the treatment of prostate cancer with irreversible electroporation is efficacious and safe.
On 17 August, a multicentre, randomised, double-blind, placebo-controlled trial—the VAPOUR trial—was published online ahead of print in The Lancet. Six-month data from the trial provide the first sham-controlled evidence in support of using the procedure.
BTG and Mirada Medical announced CE mark certification for the Simplicit90Y dosimetry software, designed to optimise the planning of Y-90 selective internal radiation therapy and facilitate personalised treatment for patients with liver cancer. CE mark certification follows approval for Simplicit90Y in Canada.
New European Society of Medical Oncology (ESMO) biliary cancer guidelines indicate yttrium-90 (Y-90) therapy as an option for post-chemotherapy treatment of intrahepatic cholangiocarcinoma.
The SOLSTICE clinical study constitutes the largest multicentre, prospective study focused on the clinical use and effectiveness of cryotherapies for patients with primary cancer lesions that have metastasised to the lung. The study was launched in 2014 by Galil Medical, which is now a part of BTG.
NEAT (Novel endovascular access trial) data presented at the Vascular Interventional Advances (VIVA) 2016 meeting (18–22 September, Las Vegas, USA) suggest that endovascular arteriovenous fistula creation using everlinQ technology (TVA Medical) is associated with almost six-fold fewer post-creation interventions and may be approximately US$11,000 cheaper than surgical fistula creation.
Timothy P Murphy, Vascular Disease Research Center, Rhode Island Hospital, Providence, USA, and one of the investigators on the CORAL study, told delegates at CIRSE 2016 in Barcelona, Spain, that a low urine albumin:creatinine ratio could be used to help identify a large group of patients with renal artery stenosis who might benefit from stenting.
InspireMD has announced 12-month follow up data from PARADIGM-101 study of the CGuard Embolic Prevention System (EPS), which were presented at the Transcatheter Cardiovascular Therapeutics symposium (TCT 2016, 29 October–2 November, Washington, DC, USA).
Shockwave Medical has announced plans for DISRUPT PAD III—what it claims is the “largest ever” multicentre randomised study to exclusively enrol patients with calcified peripheral artery disease.
The US Food and Drug Administration (FDA) has granted staged approval for Intact Vascular’s investigational device exemption (IDE) application to begin its TOBA II BTK (Tack optimised balloon angioplasty II below the knee) clinical study. The study will examine the safety and efficacy of the Tack endovascular system when used to repair dissections in the arteries below the knee following percutaneous transluminal angioplasty as a treatment for critical limb ischaemia.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos